Spruce Street Capital LP bought a new stake in shares of Savara Inc. (NASDAQ:SVRA – Free Report) during the 4th quarter, HoldingsChannel.com reports. The fund bought 2,411,093 shares of the company’s stock, valued at approximately $14,539,000. Savara accounts for about 4.8% of Spruce Street Capital LP’s holdings, making the stock its 8th biggest position.
Other large investors have also added to or reduced their stakes in the company. Prudential Financial Inc. bought a new stake in Savara in the 2nd quarter worth $30,000. BNP Paribas Financial Markets lifted its position in shares of Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares during the period. Brevan Howard Capital Management LP purchased a new position in Savara during the 2nd quarter valued at about $33,000. Russell Investments Group Ltd. lifted its position in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after acquiring an additional 9,463 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new position in Savara during the 3rd quarter valued at about $44,000. Institutional investors own 87.93% of the company’s stock.
Analyst Ratings Changes
A number of research firms have weighed in on SVRA. Oppenheimer began coverage on shares of Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective for the company. William Blair set a $10.00 price target on shares of Savara in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Savara in a research note on Monday, March 16th. Finally, Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.14.
Savara Trading Up 1.3%
SVRA stock opened at $5.33 on Tuesday. The firm has a market cap of $1.09 billion, a PE ratio of -9.52 and a beta of 0.26. The firm has a fifty day moving average price of $5.28 and a 200 day moving average price of $5.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. Savara Inc. has a fifty-two week low of $1.98 and a fifty-two week high of $7.01.
Savara (NASDAQ:SVRA – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Sell-side analysts anticipate that Savara Inc. will post -0.57 earnings per share for the current fiscal year.
Savara Company Profile
Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Further Reading
- Five stocks we like better than Savara
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA – Free Report).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
